{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T13:05:21Z","timestamp":1774011921592,"version":"3.50.1"},"reference-count":6,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.jaad.2019.06.1297","type":"journal-article","created":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T12:42:59Z","timestamp":1562157779000},"page":"e91-e92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Janus kinase inhibitors offer promise for a new era of targeted treatment for granulomatous disorders"],"prefix":"10.1016","volume":"82","author":[{"given":"Misha","family":"Rosenbach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2019.06.1297_bib1","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1001\/jamadermatol.2018.4836","article-title":"Targeted treatment of TREX1 chilblain lupus and other interferonopathies-taming T REX","volume":"155","author":"Damsky","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"26","key":"10.1016\/j.jaad.2019.06.1297_bib2","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1056\/NEJMoa1805958","article-title":"Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis","volume":"379","author":"Damsky","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2019.06.1297_bib3","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01482-2018","article-title":"Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia","volume":"52","author":"Rotenberg","year":"2018","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.jaad.2019.06.1297_bib4","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jdcr.2019.02.006","article-title":"Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera","volume":"5","author":"Wei","year":"2019","journal-title":"JAAD Case Rep"},{"issue":"6","key":"10.1016\/j.jaad.2019.06.1297_bib5","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1001\/jamadermatol.2018.0756","article-title":"Improvement in ulcerative necrobiosis lipoidica after Janus kinase-inhibitor therapy for polycythemia vera","volume":"154","author":"Lee Jonathan","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2019.06.1297_bib6","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jaad.2019.05.098","article-title":"Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare","volume":"82","author":"Damsky","year":"2020","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219322960?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219322960?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:54:08Z","timestamp":1759272848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962219322960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":6,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0190962219322960"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2019.06.1297","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Janus kinase inhibitors offer promise for a new era of targeted treatment for granulomatous disorders","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2019.06.1297","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2019.05.098","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}